Interaction Guide · Research summary

Can I take Vitamin E with Zanubrutinib?

Review Vitamin E with Zanubrutinib: possible adverse effects, preparation details, evidence limits, and sources.

Prepared by Dr. Edward M.Kim, PharmD · Clinical Director, SupplementSafety editorial team

Research summary published · Prepared · Editorial update

The short answer

Vitamin E supplements deserve review while taking zanubrutinib, especially at high doses. A direct increase in bleeding from this exact combination has not been measured.

What this answer covers

Oral zanubrutinib with vitamin E supplements. Dose and exact preparation matter; food exposures and other plant parts are distinct.

Supplement or preparation
Vitamin E
Medication ingredient
zanubrutinib

Check the prescribed treatment

This review concerns oral zanubrutinib in BRUKINSA capsules or tablets for selected blood cancers. Follow the exact product’s instructions and blood-count monitoring plan. The medicine can cause bleeding, but a drug warning alone does not prove that every supplement adds to that risk.

Why the team needs the product details

Zanubrutinib can cause serious bleeding or low platelet counts. High supplemental vitamin E can affect clotting; ordinary dietary intake is not the same exposure. The exact product and the rest of your medicines should be reviewed together.

What the human evidence does not prove

A small randomized study in warfarin users found no significant INR change with vitamin E. That does not measure every bleeding mechanism or this cancer-drug combination. It limits a universal claim but does not establish that high-dose supplementation is safe during cancer treatment.

Follow the monitoring and symptom plan

Report unusual bruising or persistent bleeding, and seek urgent help for major bleeding, black stools or vomiting blood. Keep the prescribed blood-count checks. Do not stop the cancer drug or rely on a gap between doses to prevent a possible effect on clotting.

Evidence and practical considerations

Side effects & toxicity

The drug bleeding warning and supplement-specific guidance support a conditional precaution, with human counterevidence retained.

Exact scope
Oral zanubrutinib with vitamin E supplements. Dose and exact preparation matter; food exposures and other plant parts are distinct. with RxNorm 2262435 IN zanubrutinib. Exact current oral product: BRUKINSA oral zanubrutinib capsules and tablets. Salt, formulation and regimen distinctions explicit.
Medication form and route
Oral

What remains uncertain

  • No exact co-use bleeding-outcome trial. Conditional supplement-specific bridge; healthy or other-drug null results and formulation limits retained.

Factors that may matter: Exact oral formulation and supplement preparation; Drug exposure versus clinical outcomes; Dose and duration; Platelet count and neurological symptoms.

Research conclusion: supported with conditions · Evidence assessment: moderate

Read the supporting source summaries

Source 1: Current original prescribing information

dailymed.nlm.nih.gov · Source check Sep 11, 2026

Population: Patients prescribed the exact oral formulation.

Bleeding and cytopenia warnings; CYP3A inhibitor/inducer effects. Named citrus guidance separately sourced to capsule information.

How this applies: RxNorm 2262435 IN zanubrutinib. Exact current oral product: BRUKINSA oral zanubrutinib capsules and tablets. Salt, formulation and regimen distinctions explicit.

Exact product source, not a direct study of every supplement. Population, active metabolites and formulation scope retained.

Source 2: Original official nutrient guidance

ods.od.nih.gov · Source check Sep 11, 2026

Population: Supplement users.

Can affect clotting and raise bleeding concerns.

How this applies: Conditional supplement bleeding precaution.

Not an exact target-drug co-use trial; no validated safe cutoff or food-vitamin prohibition.

Source 3: Original clinical research

pubmed.ncbi.nlm.nih.gov · Source check Sep 11, 2026

Population: 21 chronic warfarin users.

No significant INR change.

How this applies: Exact preparation/population/endpoints only; applicability to zanubrutinib independently assessed.

Abstract-only small different-drug study; INR does not capture all bleeding mechanisms.

Source 4: Medication terminology

rxnav.nlm.nih.gov · Source check Sep 11, 2026

Population: Terminology.

zanubrutinib is IN.

How this applies: Exact ingredient.

Not clinical evidence.

Research assessment: · Open full citations ↗

Review and change history

Publication status
Published research summary
Clinical review
Not yet recorded
DateUpdate
Research summary published
Article prepared
Sources checked and article drafted.

Article revision: 0c1d06dc6474ad65

This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.

Full citations require verification. Reading this answer and the source summaries does not.

Taking other supplements or medications?

Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.

Open the interaction checker

Information, not medical advice. Do not change prescribed treatment based on this guide.